| 000 | 01313 a2200361 4500 | ||
|---|---|---|---|
| 005 | 20250515090424.0 | ||
| 264 | 0 | _c20071031 | |
| 008 | 200710s 0 0 eng d | ||
| 022 | _a1743-4262 | ||
| 024 | 7 |
_a10.1038/ncponc0931 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aPan, Minggui | |
| 245 | 0 | 0 |
_aCNS response after erlotinib therapy in a patient with metastatic NSCLC with an EGFR mutation. _h[electronic resource] |
| 260 |
_bNature clinical practice. Oncology _cOct 2007 |
||
| 300 |
_a603-7 p. _bdigital |
||
| 500 | _aPublication Type: Case Reports; Journal Article | ||
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 |
_aAntineoplastic Agents _xtherapeutic use |
| 650 | 0 | 4 |
_aBrain Neoplasms _xdrug therapy |
| 650 | 0 | 4 |
_aCarcinoma, Non-Small-Cell Lung _xdrug therapy |
| 650 | 0 | 4 |
_aErbB Receptors _xantagonists & inhibitors |
| 650 | 0 | 4 | _aErlotinib Hydrochloride |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aLung Neoplasms _xgenetics |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMutation |
| 650 | 0 | 4 |
_aProtein Kinase Inhibitors _xtherapeutic use |
| 650 | 0 | 4 |
_aQuinazolines _xtherapeutic use |
| 700 | 1 | _aSantamaria, Monica | |
| 700 | 1 | _aWollman, David B | |
| 773 | 0 |
_tNature clinical practice. Oncology _gvol. 4 _gno. 10 _gp. 603-7 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1038/ncponc0931 _zAvailable from publisher's website |
| 999 |
_c17421143 _d17421143 |
||